Nuance Acquires Rights to Novel COPD Therapy From Verona in $219 Million Deal

Shanghai Nuance Pharma acquired greater China rights to a novel COPD treatment from Verona Pharma of London in a $219 million deal. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, offering both bronchodilator and anti-inflammatory effects. Verona is currently testing ensifentrine in a global Phase III trial as a maintenance treatment for chronic obstructive pulmonary disease. Nuance will make a $25 million upfront payment and a $15 million investment in Verona , plus milestones of up to $179 million and royalties. More details.... Stock Symbol: (NSDQ: VRNA) Share this with colleagues: // //